ERYP - イライテック・ファ―マ (Erytech Pharma S.A.) イライテック・ファ―マ

 ERYPのチャート


 ERYPの企業情報

symbol ERYP
会社名 Erytech Pharma SA (イライテック・ファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 エレテック・ファルマ(ERYtech Pharma SA)は、腫瘍学・血液学・免疫学分野で医薬品を開発するフランスのバイオ医薬品会社。同社は、人間の相同赤血球に取り込まるL-アスパラギナーゼからなる医薬品であるESY-ASP(GRASPA)を提供する。その製品は、急性リンパ性白血病(ALL)である小児がんの治療に使用される。   イライテック・ファ―マはフランスの製薬会社。主にがん治療法の開発に従事する。独自の技術は治療分子を赤血球に封入することに基づき、同社開発の「ERY-ASP」は急性白血病の虚弱患者を治療するソリュ―ションを提供する。同社はOrphan Europe-RecordatiとTEVAグル―プと流通パ―トナ―シップを結ぶ。生産部門と本社所在地はリヨン。   
本社所在地 Batiment Adenine 60 Avenue Rockefeller Lyon 69008 FRA
代表者氏名
代表者役職名
電話番号
設立年月日 38261
市場名 NASDAQ National Market System
ipoyear 2017年
従業員数 116人
url www.erytech.com
nasdaq_url https://www.nasdaq.com/symbol/eryp
adr_tso 5017147
EBITDA EBITDA ー
終値(lastsale) 9.2255
時価総額(marketcap) 46285689.6485
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 ERYPのテクニカル分析


 ERYPのニュース

   Phenylketonuria Treatment Market Analysis Released in Latest Industry Report 2020: BioMarin, Codexis, Erytech Pharma, SOM Innovation Biotech, Retrophin  2021/02/26 08:08:42 OpenPR
Global Phenylketonuria Treatment Market Analysis to 2027 is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Phenylketonuria Treatment market with detailed
   ERYTECH to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference  2021/01/06 21:30:00 GlobeNewswire
ERYTECH to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference Lyon (France) and Cambridge, MA (U.S.), January 6, 2021 – ERYTECH Pharma…
   ERYTECH Announces Positive Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia Presented at the American Society of Hematology Annual Meeting - Stocks News Feed  2020/12/07 07:00:00 Stocks News Feed
Webcast today, Monday, December 7at 4:00 pm CET/10:00 am ET The study confirms the potential of eryaspase as an attractive treatment option for ALL patients with hypersensitivity to PEG-asparaginase LYON, France and CAMBRIDGE, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) — ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating… Read More »ERYTECH Announces Positive Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia Presented at the American Society of Hematology Annual Meeting
   Erytech Pharma ADR Quartalszahlen: Gewinnerwartung und Umsatzprognose im Q3 entspricht dem Konsens  2020/11/06 00:00:00 Investing.com Germany
Erytech Pharma ADR Quartalszahlen: Gewinnerwartung und Umsatzprognose im Q3 entspricht dem Konsens
   ERYTECH secures €10M in non-dilutive financing (NASDAQ:ERYP)  2020/11/02 10:04:03 Seeking Alpha
ERYTECH Pharma (NASDAQ:ERYP) has received approval for for a total of €10M in non-dilutive financing from Bpifrance and Société Générale in the form of St
   Phenylketonuria Treatment Market Analysis Released in Latest Industry Report 2020: BioMarin, Codexis, Erytech Pharma, SOM Innovation Biotech, Retrophin  2021/02/26 08:08:42 OpenPR
Global Phenylketonuria Treatment Market Analysis to 2027 is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Phenylketonuria Treatment market with detailed
   ERYTECH to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference  2021/01/06 21:30:00 GlobeNewswire
ERYTECH to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference Lyon (France) and Cambridge, MA (U.S.), January 6, 2021 – ERYTECH Pharma…
   ERYTECH Announces Positive Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia Presented at the American Society of Hematology Annual Meeting - Stocks News Feed  2020/12/07 07:00:00 Stocks News Feed
Webcast today, Monday, December 7at 4:00 pm CET/10:00 am ET The study confirms the potential of eryaspase as an attractive treatment option for ALL patients with hypersensitivity to PEG-asparaginase LYON, France and CAMBRIDGE, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) — ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating… Read More »ERYTECH Announces Positive Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia Presented at the American Society of Hematology Annual Meeting
   Erytech Pharma ADR Quartalszahlen: Gewinnerwartung und Umsatzprognose im Q3 entspricht dem Konsens  2020/11/06 00:00:00 Investing.com Germany
Erytech Pharma ADR Quartalszahlen: Gewinnerwartung und Umsatzprognose im Q3 entspricht dem Konsens
   ERYTECH secures €10M in non-dilutive financing (NASDAQ:ERYP)  2020/11/02 10:04:03 Seeking Alpha
ERYTECH Pharma (NASDAQ:ERYP) has received approval for for a total of €10M in non-dilutive financing from Bpifrance and Société Générale in the form of St
   Phenylketonuria Treatment Market Analysis Released in Latest Industry Report 2020: BioMarin, Codexis, Erytech Pharma, SOM Innovation Biotech, Retrophin  2021/02/26 08:08:42 OpenPR
Global Phenylketonuria Treatment Market Analysis to 2027 is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Phenylketonuria Treatment market with detailed
   ERYTECH to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference  2021/01/06 21:30:00 GlobeNewswire
ERYTECH to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference Lyon (France) and Cambridge, MA (U.S.), January 6, 2021 – ERYTECH Pharma…
   ERYTECH Announces Positive Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia Presented at the American Society of Hematology Annual Meeting - Stocks News Feed  2020/12/07 07:00:00 Stocks News Feed
Webcast today, Monday, December 7at 4:00 pm CET/10:00 am ET The study confirms the potential of eryaspase as an attractive treatment option for ALL patients with hypersensitivity to PEG-asparaginase LYON, France and CAMBRIDGE, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) — ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating… Read More »ERYTECH Announces Positive Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia Presented at the American Society of Hematology Annual Meeting
   Erytech Pharma ADR Quartalszahlen: Gewinnerwartung und Umsatzprognose im Q3 entspricht dem Konsens  2020/11/06 00:00:00 Investing.com Germany
Erytech Pharma ADR Quartalszahlen: Gewinnerwartung und Umsatzprognose im Q3 entspricht dem Konsens
   ERYTECH secures €10M in non-dilutive financing (NASDAQ:ERYP)  2020/11/02 10:04:03 Seeking Alpha
ERYTECH Pharma (NASDAQ:ERYP) has received approval for for a total of €10M in non-dilutive financing from Bpifrance and Société Générale in the form of St

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 イライテック・ファ―マ ERYP Erytech Pharma S.A.)

 twitter  (公式ツイッターやCEOツイッターなど)